Zacks Investment Research
Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
Zevra Therapeutics reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.14, with revenues of $37.76 million exceeding expectations by 2.77%. The company has outperformed market estimates in four consecutive quarters.
However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Cronos Group is expected to report Q3 results on November 5, with projected earnings of $0.03 per share, down 57.1% year-over-year, though revenues are expected to grow 30.6%.
